Kerr on Oncology

David J. Kerr, MD, is a professor of cancer medicine at the University of Oxford in Oxford, England. He is recognized internationally for his work in the research and treatment of colorectal cancer, and has published more than 400 papers. He has founded three university spin-out companies: COBRA Therapeutics, Celleron Therapeutics, and Oxford Cancer Biomarkers. In 2002, he was appointed Commander of the British Empire by Queen Elizabeth and in 2010 was elected president of the European Society for Medical Oncology.

+ Add to Email Alerts

The Case for 'Safe' Step Therapy David Kerr discusses step therapy, focusing on the potential to provide more access to innovative cancer medicines globally.
Medscape Oncology, May 02, 2022
A 'Wake-Up' Call to Resolve UK Cancer Drug Access David Kerr questions the policy that patients in Scotland with prostate cancer have access to olaparib, yet patients in the rest of the United Kingdom do not.
Medscape Oncology, April 26, 2022
Let's Do More to Support Ukrainian Refugees with Cancer Oncologist David Kerr pays tribute to colleagues who are helping Ukrainian patients with cancer flee the war.
Medscape Oncology, March 23, 2022
Focusing Cancer Resources After the Pandemic: Best Practices Professor David Kerr discusses a recent article providing a clear base on which to start to rebuild health economies of low- and middle-income countries after the COVID-19 pandemic.
Medscape Oncology, March 11, 2022
We're Finally Beginning to Crack the KRAS Nut in Colorectal Cancer After 30 years, we may at last have drugs to treat KRAS G12C-mutant colorectal cancer.
Medscape Oncology, March 08, 2022
Should Physicians Run Health Departments? Physicians are on the front lines of delivering healthcare, but does that make them effective leaders in determining health policy?
Medscape Oncology, March 04, 2022
Germline Signatures of Toxicity: A Fertile Field Dr David Kerr discusses a recent genome-wide association study conducted to investigate germline signatures of toxicity.
Medscape Oncology, December 23, 2021
Medicine, but Not Law, Runs in Families David Kerr discusses whether medicine runs in families and presents data from a Swedish study suggesting that increasingly more physicians have a parent who is also a physician.
Medscape Oncology, December 22, 2021
Is Christmas Cost-Effective? Prof David Kerr discusses the cost-effectiveness of Christmas.
Medscape Oncology, December 16, 2021
Liposomal Irinotecan May Benefit Biliary Tract Cancer David Kerr discusses the potential role of liposomal irinotecan in patients with metastatic biliary tract cancer.
Medscape Oncology, December 08, 2021
The Never-Ending Global Struggle With Drug Costs How can we make innovative drugs available to low-income countries when we cannot even get affordable generics to them?
Medscape Oncology, November 16, 2021
What Happens if a Multidisciplinary Tumor Board Cannot Agree? Professor David Kerr discusses what may happen when a multidisciplinary tumor board cannot reach a decision on a case.
Medscape Oncology, October 29, 2021
Mobile Phone App Helps to Deliver Palliative Care Dr David Kerr discusses a recent study of a mobile phone app designed to collect palliative outcomes data in sub-Saharan Africa.
Medscape Oncology, October 11, 2021
ESMO 2021 ESMO CRC Data Showcase 'Beauty' of Precision Medicine Prof David Kerr discusses recent studies in colorectal cancer with molecularly based hypotheses.
Medscape Oncology, October 08, 2021
Massive Study Shows Impact of Colorectal Cancer Screening David Kerr discusses a study of 3.1 million Europeans that illustrates the impact of national screening programs on colorectal cancer incidence, burden, and mortality.
Medscape Oncology, October 07, 2021
Safe to Omit Bolus in 5-FU for Colorectal Cancer? David Kerr discusses a recent study investigating the need for bolus 5-FU in the chemotherapy regimen for colorectal cancer.
Medscape Oncology, October 04, 2021
Procuring Anticancer Drugs: Lessons From Uganda Dr David Kerr discusses a recent article on the procurement of anticancer drugs and the potential to improve access to these essential cancer medicines.
Medscape Oncology, August 24, 2021
What Do You Do to Blow Off Steam? David Kerr plays drums in a 'rock and roll' ceilidh band.
Medscape Oncology, July 09, 2021
ASCO 2021 New Data Support De-escalating Chemotherapy in Colorectal Cancer KEYNOTE-177 reaffirms pembro in mismatch repair-deficient colorectal cancer, and two other studies support easing off chemo to improve PFS in advanced disease.
Medscape Oncology, June 29, 2021
Steve's Plastic Lawn: A Dying Man's Tribute to His Wife A conversation with a long-term patient sets David Kerr to thinking about what kind of lasting memorials we leave behind.
Medscape Oncology, May 19, 2021

No Results